Enlivex Ltd. (NASDAQ: ENLV) completed a $21 million debt financing agreement with The Lind Partners, providing net proceeds of approximately $18.7 million before expenses. The convertible note allows conversion to ordinary shares at a fixed price of $2.69175 per share, representing a 264% premium to the March 20, 2026 Nasdaq closing price.

The company exercised an option to purchase 3,030,303,030 RAIN tokens at $0.0033 per token for $10 million, which represents a 62% discount to the March 22, 2026 closing price. Enlivex and the Rain Foundation extended the duration of an option to acquire up to 272,121,212,121 additional RAIN tokens at the same $0.0033 price from November 30, 2026 to December 31, 2027.

The board of directors approved a share repurchase program allowing the company to buy back up to $20 million of outstanding ordinary shares, subject to regulatory requirements. The program has no expiration date and may be modified or terminated at any time.

"We are continuing to execute our prediction markets treasury strategy," said Shai Novik, Executive Chairman. He noted the RAIN token has been trading in a range of approximately $0.008-$0.01 per token during the last 30 trading days.

CEO Oren Hershkovitz stated the company believes its share price represents a discount to the market value of its treasury and treasury-related assets. H.C. Wainwright & Co. served as placement agent for the debt financing.

Enlivex operates as a quality longevity company with a prediction markets treasury strategy built around the RAIN protocol on Arbitrum. The company is developing Allocetra, an immunotherapy targeting inflammatory conditions associated with aging.